Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 331 to 340 of 851

TitleReference numberPublishedLast updated
Sodium zirconium cyclosilicate for treating hyperkalaemiaTA599
Cabotegravir with rilpivirine for treating HIV-1TA757
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsyTA758
Belimumab for treating active autoantibody-positive systemic lupus erythematosusTA752
Mogamulizumab for previously treated mycosis fungoides and Sézary syndromeTA754
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal)TA750
Dupilumab for treating severe asthma with type 2 inflammationTA751
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disordersTA748
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)TA749
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancerTA746

Results per page

  1. 10
  2. 25
  3. 50
  4. All